By Karen Roman Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it started a global product license agreement with Catalent, Inc., enabling the latter to include Lisata’s certepetide into antibody-drug conjugates (ADCs) developed using Catalent’s SMARTag technology platform. The partnership is a validation of certepetide’s versatility and positions Lisata’s technology within a leading ADC platform, the company stated. Catalent acquires non-exclusive rights to develop and commercialize products with certepe ...